NCT06068400View on ClinicalTrials.gov

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Multiple Myeloma in Relapse
Interventions
BIOLOGICAL

BCMA/GPRC5D double CAR-T

BCMA/GPRC5D double CAR-T is a new type CAR-T cells therapy for patients with Multiple Myeloma.

Trial Locations (1)

518000

RECRUITING

Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen

All Listed Sponsors
lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY